Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP865136.RAEX0EEPRAFnIMafgl_TsqQcptm2HiFeM-OSg9ByxsQgE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP865136.RAEX0EEPRAFnIMafgl_TsqQcptm2HiFeM-OSg9ByxsQgE130_assertion type Assertion NP865136.RAEX0EEPRAFnIMafgl_TsqQcptm2HiFeM-OSg9ByxsQgE130_head.
- NP865136.RAEX0EEPRAFnIMafgl_TsqQcptm2HiFeM-OSg9ByxsQgE130_assertion description "[In addition to the higher risk for exudative AMD in patients with the CFH 402HH genotype that was found in previous studies, our results show that the CFH 402HH genotype also correlates with lower visual acuity outcome after treatment with bevacizumab, suggesting that pharmacogenetics of CFH plays a role in response to treatment of wet AMD.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP865136.RAEX0EEPRAFnIMafgl_TsqQcptm2HiFeM-OSg9ByxsQgE130_provenance.
- NP865136.RAEX0EEPRAFnIMafgl_TsqQcptm2HiFeM-OSg9ByxsQgE130_assertion evidence source_evidence_literature NP865136.RAEX0EEPRAFnIMafgl_TsqQcptm2HiFeM-OSg9ByxsQgE130_provenance.
- NP865136.RAEX0EEPRAFnIMafgl_TsqQcptm2HiFeM-OSg9ByxsQgE130_assertion SIO_000772 21232084 NP865136.RAEX0EEPRAFnIMafgl_TsqQcptm2HiFeM-OSg9ByxsQgE130_provenance.
- NP865136.RAEX0EEPRAFnIMafgl_TsqQcptm2HiFeM-OSg9ByxsQgE130_assertion wasDerivedFrom befree-2016 NP865136.RAEX0EEPRAFnIMafgl_TsqQcptm2HiFeM-OSg9ByxsQgE130_provenance.
- NP865136.RAEX0EEPRAFnIMafgl_TsqQcptm2HiFeM-OSg9ByxsQgE130_assertion wasGeneratedBy ECO_0000203 NP865136.RAEX0EEPRAFnIMafgl_TsqQcptm2HiFeM-OSg9ByxsQgE130_provenance.